GleamWall
中文EN

CELZ CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1187953 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-50.0%
TTM net income YoY-25.4%
TTM EPS YoY29.9%
Revenue 3-yr CAGR-50.4%
Net income 3-yr CAGR—

Margins

Gross margin66.9%
Operating margin-256,435.0%
Net margin-249,160.1%
FCF margin—
EBITDA margin—

Returns

ROE-119.2%
ROA-113.8%
ROIC (approx.)-3,736.6%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets4.0%
Debt / equity0.00x
Current ratio23.66x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.86x
Accruals ratio-16.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$6,000$11,000
Cost of revenue$2,194$4,400
Gross profit$3,806$6,600
R&D expense$2.26M$2.40M
SG&A expense$3.76M$3.24M
Operating income-$6.14M-$5.74M
Pretax income-$6.00M-$5.49M
Income tax$0$0
Net income-$6.00M-$5.49M
EBITDA—-$5.69M
EPS (diluted)-2.52-3.71
Weighted avg. shares (diluted)2.38M1.48M
Balance sheet
Cash & equivalents$7.21M$5.94M
Inventory$0$2,194
Current assets$7.40M$6.14M
Intangibles$407,230$530,559
Total assets$7.81M$6.67M
Current liabilities$284,880$327,644
Total liabilities$284,880$327,644
Shareholders' equity$7.51M$6.34M
Shares outstanding3.70M1.75M
Cash flow statement
Operating cash flow-$5.86M-$5.30M
Investing cash flow-$50,500$6.32M
Financing cash flow$7.17M$1.45M
Depreciation & amortization—$56,000
Stock-based compensation$3,485$36,648
Share buybacks$10,000$174,964

Free plan shows the latest 2 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.